Table 1.
Baseline Characteristics for ACS, Stable CAD, and Control Groups
| ACS | Stable CAD | Controls | P Value | |
|---|---|---|---|---|
| Number | 40 | 33 | 10 | — |
| Age, y—mean (SD) | 64.5 (10.2) | 61.1 (10.3) | 61.3 (6.7) | 0.32 |
| Female (%) | 3 (8) | 3 (9) | 3 (30) | 0.29 |
| Diabetes mellitus (%) | 13 (33) | 13 (39) | 2 (20) | 0.42 |
| Hypertension (%) | 27 (68) | 19 (58) | 3 (30) | 0.06 |
| Dyslipidemia (%) | 27 (68) | 23 (70) | 5 (50) | 0.68 |
| Current smoker (%) | 10 (25) | 6 (18) | 3 (30) | 0.70 |
| Previous MI (%) | 7 (18) | 10 (30) | 1 (10) | 0.28 |
| Previous PCI (%) | 7 (18) | 9 (27) | 0 (0) | 0.17 |
| Previous CABG (%) | 1 (3) | 6 (18) | 0 (0) | 0.05 |
| Medications | ||||
| Aspirin (%) | 40 (100) | 33 (100) | 8 (80) | 0.134 |
| Thienopyridines (%) | 38 (95) | 26 (79) | 6 (60) | 0.017 |
| β-Blockers (%) | 30 (75) | 17 (52) | 3 (30) | 0.023 |
| ACE-I/ARA-2 (%) | 25 (63) | 20 (61) | 4 (40) | 0.331 |
| Statins (%) | 36 (90) | 27 (82) | 7 (70) | 0.115 |
| Hypoglycemics (%) | 12 (30) | 12 (36) | 1 (10) | 0.231 |
| Insulin (%) | 3 (8) | 2 (6) | 0 (0) | 1 |
ACE-I indicates angiotensin-converting enzyme inhibitors; ACS, acute coronary syndrome; ARA-2, angiotensin 2 receptor antagonist; CABG, coronary artery bypass graft surgery; MI, myocardial infarction; PCI, percutaneous coronary intervention; CAD, coronary artery disease.